Nivolumab, an anti-PD-1 monoclonal antibody, is being evaluated for its efficacy in patients with hematologic malignancies that are relapsed or refractory post CAR T-cell therapy. The trial is sponsored by the University of Washington in collaboration with Bristol-Myers Squibb, indicating a strong interest from a major industry player. The market for immunotherapy in hematologic cancers is expanding, particularly for patients who have limited treatment options after CAR T-cell therapy. Successful outcomes could position nivolumab as a critical treatment option in this niche, potentially leading to increased market share and revenue for both the University of Washington and Bristol-Myers Squibb. Diligence should focus on competitive landscape analysis, particularly regarding other PD-1/PD-L1 inhibitors and emerging therapies targeting similar patient populations.